Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM)
Interventions: Drug: Lymphodepleting chemotherapy: Cyclophosphamide; Drug: Lymphodepleting chemotherapy: Bendamustine; Drug: Lymphodepleting chemotherapy: Fludarabine; Other: Lisocabtagene Maraleucel; Other: Axicabtagene Ciloleucel; Other: Ciltacabtagene Autoleucel; Radiation: Low-Dose Total Body Irradiation
Sponsors: Weill Medical College of Cornell University
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
